openPR Logo
Press release

Open Therapeutics Receives Oklahoma Medical Research Foundation’s Dormant Intellectual Property.

08-08-2018 10:17 AM CET | Health & Medicine

Press release from: Open Therapeutics

/ PR Agency: Somerville Associates
Open Therapeutics Receives Oklahoma Medical Research Foundation’s Dormant Intellectual Property.

The intellectual property is available on the scientific collaboration platform, Therapoid™.

Minneapolis, MN– August 7, 2018 – Open Therapeutics LLC, a scientific collaboration platform company, received dormant intellectual property (IP) from the Oklahoma Medical Research Foundation (OMRF).

According to Jason E. Barkeloo, Founder and Chair of Open Therapeutics, “Open Therapeutics in-licenses and accepts dormant, orphan, and abandoned IP from institutions and organizations around the world. That IP is freely provided to scientists on the Therapoid™ platform. Along with grants, lab equipment, communication tools, manuscript development tool, career opportunities, and preprint server, researchers can collaborate with peers to advance the freely provided IP.”

The OMRF IP available in Therapoid™ ranges from proteins and a central nervous system treatment for Alzheimer’s, to novel multiple sclerosis (MS) treatments and pluripotent stem cells.

According to Jerome Hamilton, “We are pleased to represent this intellectual property from the Oklahoma Medical Research Foundation as we do our part in making the world a better place with therapeutic discoveries. Open Therapeutics will continue to add value for scientists while facilitating a world class experience as they collaborate with their peers on the Therapoid™ platform.”

The OMRF IP is listed on the Therapoid™ platform, which is in alpha release at https://Therapoid.net.

About Open Therapeutics LLC
Open Therapeutics (http://OpenTherapeutics.org) is an intellectual property firm that creates and attracts therapeutic technologies and crowdsources them for use by the global scientific community. Researchers can freely access the intellectual properties, funding, lab equipment, manuscript development tool, and preprint server to further the development of the therapeutic technologies (medical devices, pharma, diagnostics) at Therapoid™ (https://Therapoid.net). The Company is headquartered in Minneapolis, MN, with operations in Cincinnati, OH, Amman, Jordan, and Bangalore, India.

Contact: Jerome Hamilton, CEO, Open Therapeutics
+1.651.900.0412
Jerome@OpenTherapeutics.org
Twitter: @OpenTherapeutic
Telegram: https://t.me/OpenTherapeutics

Open Therapeutics (http://OpenTherapeutics.org) is an intellectual property firm that creates and attracts therapeutic technologies and crowdsources them for use by the global scientific community. Researchers can freely access the intellectual properties, funding, lab equipment, manuscript development tool, and preprint server to further the development of the therapeutic technologies (medical devices, pharma, diagnostics) at Therapoid™ (https://Therapoid.net). The Company is headquartered in Minneapolis, MN, with operations in Cincinnati, OH, Amman, Jordan, and Bangalore, India.

Open Therapeutics
P.O. Box 30085
Cincinnati, OH 45230

Contact: Jerome Hamilton, CEO, Open Therapeutics
+1.651.900.0412

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Open Therapeutics Receives Oklahoma Medical Research Foundation’s Dormant Intellectual Property. here

News-ID: 1167567 • Views: 164

More Releases from Open Therapeutics

Timmaron Group of Minnesota invests in Open Therapeutics, LLC
Open Therapeutics, LLC owns Therapoid. Therapoid is a scientific collaboration platform that crowdsources scientists, particularly the underserved in Africa, Asia, and Latin America, around freely provided Intellectual property. Therapoid not only provides IP, but grants, free lab equipment, manuscript development tools, and preprint server for achieving open access publications and pushing technology development forward. For more information about Open Therapeutics visit (https://OpenTherapeutics.org) or visit (https://Therapoid.net) to register.
Open Therapeutics Launches Strategic Partnership with The Knight Group
Open Therapeutics, a St. Paul, MN based company that curates and develops open medical, biopharma and synthetic biology-based biotechnologies, has entered into a strategic partnership with The Knight Group, a Cleveland based executive search firm specializing in scientific staffing. The Knight Group, led by CEO Ray Knight, will source talent via internal resources and Open Therapeutics’ Therapoid web platform under the auspices of a shared revenue model. “This venture,
Open Therapeutics Announced as a Winner of Freedom from Cancer Startup Challenge
Minneapolis, MN and Bethesda, MD – July 26, 2018 – Open Therapeutics LLC, a scientific collaboration platform company, is a winner of the Center for Advancing Innovation (CAI) Freedom from Cancer Startup Challenge (FCSC). The FCSC, generously supported by the Laura and John Arnold Foundation and MedImmune®, has an overarching goal to advance more than one hundred inventions to prevent, diagnose and/or treat cancer. The inventions were developed at fifty-five institutions,
Open Therapeutics and doDOC™ Partner to Integrate doDOC™ Content Management …
Open Therapeutics and doDOC™ Partner to Integrate doDOC™ Content Management System into Therapoid™. Innovative manuscript development tool to be integrated into scientific collaboration platform. Minneapolis, MN and Boston, MA – June 27, 2018 – Open Therapeutics LLC, a scientific collaboration platform company, and doDOC, a online collaborative writing tool that allows researchers to plan, draft, edit, review and approve professional documents more than 70% faster, have partnered. Therapoid™ will freely

All 5 Releases


More Releases for Therapoid™

Timmaron Group of Minnesota invests in Open Therapeutics, LLC
Open Therapeutics, LLC owns Therapoid. Therapoid is a scientific collaboration platform that crowdsources scientists, particularly the underserved in Africa, Asia, and Latin America, around freely provided Intellectual property. Therapoid not only provides IP, but grants, free lab equipment, manuscript development tools, and preprint server for achieving open access publications and pushing technology development forward. For more information about Open Therapeutics visit (https://OpenTherapeutics.org) or visit (https://Therapoid.net) to register.
Open Therapeutics Launches Strategic Partnership with The Knight Group
Open Therapeutics, a St. Paul, MN based company that curates and develops open medical, biopharma and synthetic biology-based biotechnologies, has entered into a strategic partnership with The Knight Group, a Cleveland based executive search firm specializing in scientific staffing. The Knight Group, led by CEO Ray Knight, will source talent via internal resources and Open Therapeutics’ Therapoid web platform under the auspices of a shared revenue model. “This venture,
Open Therapeutics Announced as a Winner of Freedom from Cancer Startup Challenge
Minneapolis, MN and Bethesda, MD – July 26, 2018 – Open Therapeutics LLC, a scientific collaboration platform company, is a winner of the Center for Advancing Innovation (CAI) Freedom from Cancer Startup Challenge (FCSC). The FCSC, generously supported by the Laura and John Arnold Foundation and MedImmune®, has an overarching goal to advance more than one hundred inventions to prevent, diagnose and/or treat cancer. The inventions were developed at fifty-five institutions,
Open Therapeutics and doDOC™ Partner to Integrate doDOC™ Content Management …
Open Therapeutics and doDOC™ Partner to Integrate doDOC™ Content Management System into Therapoid™. Innovative manuscript development tool to be integrated into scientific collaboration platform. Minneapolis, MN and Boston, MA – June 27, 2018 – Open Therapeutics LLC, a scientific collaboration platform company, and doDOC, a online collaborative writing tool that allows researchers to plan, draft, edit, review and approve professional documents more than 70% faster, have partnered. Therapoid™ will freely